article
Breakthrough for pancreatic cancer treatment
Researchers have designed the first small molecule drug targeting K-Ras GD12, which could improve pancreatic cancer outcomes.
List view / Grid view
Clinical Trials
article
Natural killer cells: Looking good for cancer therapy
17 November 2023 | By
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, but is this belief at the present stage of development of the immune therapy field?
article
Exploring alternatives to animal testing in drug discovery
The use of animal studies in drug development has become a growing ethical concern, particularly given the high failure rate of clinical trials, which can reach up to 90 percent. This article highlights non-animal models that could expedite the drug delivery process from bench to bedside.
whitepaper
Under the microscope: Sustaining momentum in iPSC-derived allogeneic cell therapies
Drug Target Review connects with Dr Stefan Braam, co-founder and CTO of Cellistic, and Andy Holt, CCO of Cellistic, for a rundown on today’s landscape for allogeneic cell therapies.
news
FDA clears Cellenkos IND application for potential ALS treatment
Following FDA clearance, Cellenkos will initiate Phase I and Phase Ib trials of CK0803, allogeneic regulatory T cells, in patients with ALS.
news
China approves IND application for Everest Medicines novel BTK inhibitor
The Chinese National Medical Products Administration has approved a Phase Ib study of Everest Medicines' EVER001, for potential treatment of glomerular diseases.
news
Silo Pharma initiates pre-IND package for ketamine to treat fibromyalgia
Silo Pharma says it is preparing a pre-IND package and meeting with the FDA for a topical formulation of ketamine to treat fibromyalgia.
news
FDA accepts IND application for Clarametyx antibody therapy CMTX-101
Clarametyx says the FDA has accepted an IND application for first-in-human trials of CMTX-101, an antibody to treat bacterial pneumonia.
article
Building a powerful portfolio of sepsis biomarker signatures for therapeutic clinical trials
In this Q&A, Immunexpress Chief Executive Officer Dr Rolland Carlson and Chief Scientific Officer Dr Richard Brandon discuss key aspects for molecular diagnostic discovery and development platforms, including how to best leverage microarray and next-generation sequencing (NGS) tools.
article
The potential of Ayurvedic medicine
In a recent study, scientists have highlighted the possible use of South Asian medicine, specifically, Ayurvedic medicine, to treat type 2 diabetes. In this article, Drug Target Review dives into the study’s implications and what it means for the western world of drug discovery.
news
VBI Vaccines announces progress from coronavirus programme
Pre-clinical research from VBI Vaccines has demonstrated an encouraging ability to boost and broaden the immune response against the coronavirus Beta variant.
news
Simple delivery method that enhances a promising cancer treatment
Scientists have developed a delivery method that enhances treatment by adding CAR T cells and specialising signalling proteins to a hydrogel that is injected next to a tumour.
article
Neutralising SARS-CoV-2 with intranasally-delivered antibodies
A monoclonal antibody (mAb) developed by IGM Biosciences to combat COVID-19 has shown success in pre-clinical studies and has now moved into Phase I trials. In this Q&A, Dr Chris Takimoto, Chief Medical Officer at IGM Biosciences, explains how this biotherapeutic works to prevent and treat SARS-CoV-2 infection.
news
Pre-clinical study shows significant increase in effectiveness of breast cancer immunotherapy
Scientists have discovered the essential role of a ligand-dependent corepressor to potentially enable cancer cells to present tumour antigens on their surfaces.
news
Study provides possible answers to why immunotherapy for ovarian cancers often fails
New research has discovered metabolic mechanisms that contribute to how ovarian cancer escapes from immune attack and how combination therapies can exploit these pathways to improve ovarian cancer treatment.
